Ophthalmology News

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.

NEW YORK — In this Healio Video Perspective from OSN New York, John P. Berdahl, MD, shares pearls on how to decide between LASIK or PRK for patients who previously underwent cataract surgery.

AlloVir, an allogeneic T cell immunotherapy company, will merge with Kalaris Therapeutics to focus on retinal diseases, according to a press release.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Peter K. Kaiser, MD, of Ocular Therapeutix, discusses the company’s shift to a retina-focused program.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Jordi Monés, MD, PhD, discusses an investigational optogenetic therapy for geographic atrophy.

NEW YORK — In this Healio Video Perspective from OSN New York, Nandini Venkateswaran, MD, of Massachusetts Eye and Ear Infirmary, discusses real-world data investigating the use of Dextenza in patients with glaucoma.

What risks should we accept in exchange for a miracle?

The FDA has extended its Prescription Drug User Fee Act date for the biologics license application for NT-501, a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.

Recent research has suggested that GLP-1 agonists used to treat obesity might be associated with a stroke in the optic nerve, but association is not the same as causation.

A paper recently published in JAMA Ophthalmology by Hathaway and colleagues at Harvard suggested a potential association between prescribed semaglutide and an increased risk for nonarteritic anterior ischemic optic neuropathy.